Angle Share Price (AGL)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Angle Plc	LSE:AGL	London	Ordinary Share	GB0034330679	ORD 10P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	-1.70p	-3.32%	49.50p	154,364	14:08:57

Bid Price		Offer Price	High Price	Low Price	Open Price
49.00p		50.00p	51.20p	49.00p	51.20p

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Support Services	0.63	-8.93	-10.09		70.5

Related Shares
Experian (EXPN), Ferguson (FERG), PHSC Plc (PHSC), Nakama (NAK)

Angle (AGL) Latest News

Angle News

Date	Time	Source	Headline
25/7/2018	12:26	ALNC	Angle Annual Loss Widens As It Progresses Parsortix Regulatory Tests
25/7/2018	07:32	ALNCF	Alliance News Flash Headline
25/7/2018	07:00	UKREG	Angle PLC Preliminary Results for year ended 30 April 2018
24/7/2018	17:42	UKREG	Angle PLC EIS/VCT Advance Assurance and Total Voting Rights
18/7/2018	10:34	UKREG	Angle PLC Result of General Meeting
02/7/2018	07:00	UKREG	Angle PLC Notice of Preliminary Results
25/6/2018	18:34	ALNC	UPDATE: ANGLE Raises GBP12.7 Million Through Share Placing (ALLISS)
25/6/2018	18:20	UKREG	Angle PLC Results of Fundraising
25/6/2018	14:58	UKREG	Angle PLC Close of Accelerated Bookbuild
25/6/2018	10:36	ALNC	ANGLE To Raise GBP12 Million Through 24 Million Share Placing (ALLISS)

More Angle News

Angle Takeover Rumours

Angle (AGL) Share Charts

1 Year Angle Chart

1 Month Angle Chart

Intraday Angle Chart

Angle (AGL) Discussions and Chat

Angle Forums and Chat

Date	Time	Title	Posts
17/8/2018	16:00	ANGLE 2016 – LIQUID BIOPSY TAKEOVER TARGET	9,954
02/7/2018	12:06	Still time to look at Angle (AGL)	-
14/5/2018	09:44	ANGLE (AGL) Strategic Move	-
16/3/2017	20:00	ANGLE [12.75p] TARA*S SHARE OF THE DECADE "TARGET PRICE Ј100.00 PER SHARE."	3,646
08/10/2016	12:43	Angle PLC 2011	30,115

Add a New Thread

Angle (AGL) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
2018-08-17 15:23:26	49.75	1,939	964.65	O
2018-08-17 14:03:14	49.75	5,015	2,494.96	O
2018-08-17 13:47:38	49.75	3,000	1,492.50	O
2018-08-17 13:11:02	49.15	785	385.83	O
2018-08-17 13:06:03	48.30	1,000	483.00	O

View all Angle trades in real-time

Angle (AGL) Top Chat Posts

Date	Subject
18/8/2018 09:20	Angle Daily Update: Angle Plc is listed in the Support Services sector of the London Stock Exchange with ticker AGL. The last closing price for Angle was 51.20p. Angle Plc has a 4 week average price of 49p and a 12 week average price of 49p. The 1 year high share price is 60.50p while the 1 year low share price is currently 32.25p. There are currently 142,486,522 shares in issue and the average daily traded volume is 67,774 shares. The market capitalisation of Angle Plc is £70,530,828.39. Read Full Thread Reply
25/7/2018 19:47	alloa2003: Hi MorganK, I have said this a few times now, I think the risk reward ratio comparing the share price to the possible price if FDA approval is gained is very much on the side of caution. The gap is just too big as we approach make or break bearing in mind what we already know. It must be a great arbitrage situation for those who work purely on the risk/reward ratio. I too believe we will see the share price gradually rise in anticipation. Read Full Thread Follow Reply
24/7/2018 19:00	alloa2003: Longterm, I cannot get my head around why so many people are concerned about dilution. If the product does anywhere near what the company expects then the share price will be a multiple of what it is now. We are not talking about a company selling clothing, food or shoes, we are talking about a one product company which is actually a sh*t hot or bust investment. I can see what you might mean about the second placing but what do you want the company to do? Wait until further down the line when they need more money and more importantly the market knows they need more money. This is when the vultures hover, sell short and push the price down and down increasing the dilution. You could argue the management was behind the ball and slow to react with the first placing but the second placing is simply a case of raising money when you can, when maybe you dont need it immediately. But it does take away any potential funding issues in the short to medium term. As far as the first placing goes, without this there would be no company. So it is beyond me why people still complain about dilution with the rescue fund raising when in reality there would have been no company without it. Also, when a small company is trying to raise a decent amount of money there will always be significant dilution simply because of the size of the company. Quite how you expect the company to "resolve" the dilution issues is beyond me. I think some people get mixed up between the idea of dilution and actual existance. If the share price doubles, trebles or more then personally I could not give a hoot about dilution. Read Full Thread Follow Reply
09/7/2018 11:25	jelenko: The question is how much would we charge for a license? I think good trial results and the share price would start to factor in FDA approval. Remember how quickly it raced to 79p on the Bart's prostate news last year. This time the magnitude of the rise would be greater, I think we all know that. I have a simple way of looking at the share price potential especially when we have a meaningful revenue number( at some future date) Every £10m in revenue @75% margin and 15 PE would equate to 79p share price. Every £100m in revenue £790p. The market is enormous and you would think that with FDA £100m should be easily attainable. Especially when the market size the company talks about is valued in £bilions. Read Full Thread Follow Reply
09/5/2018 12:49	bones698: Waterloo nice to see some sense on here for a change . We both agree the potential is there my view is though will agl deliver . I also have concerns that in other countries where they have received the required approval that no sales are being generated years after they received them which begs the question why aren't fast they taking up parasotix if it's so good ???? The sales agreements seem to be delivering nothing again this is concerning and the pace agl moves at seems to point to a lot more money needing to be raised to get to the point of a profit if they ever get there . I have seen many potential market making inventions come and go without ever getting close and unfortunately I see the same thing here if I'm honest . To me the share price isn't warranted and should still be hovering around the right price until progress is shown on any front . The cash they raised is being eaten into at a fair rate of knots so it won't be long before that scenario comes round again to haunt shareholders . Remember they will savage the share price prior to any mention as the city gets wind of them needing cash just like last time only next will be even worse . Read Full Thread Follow Reply
26/3/2018 09:17	alloa2003: I think AGL share price suffers from boredom at times between announcements. Very news driven as profitability is some way off. Read Full Thread Follow Reply
25/3/2018 13:01	miavoce: I've been invested in AGL for many years and I am fully familiar with the typical volume of trading and the share price behaviour. Maybe to aid your credibility on this thread you could perhaps comment on the likely forthcoming newsflow and its potential impact on the share price The combination of sensitivity and specificity which is achieved by the AGL test outperforms the two existing tests which either have much weaker sensitivity or much weaker specificity. Read Full Thread Follow Reply
25/3/2018 12:37	pwhite73: miavoce - "I don't think PWhite realises that he / she is talking to a group of long term investors in Angle.." Over the years I have seen many a long term investors and supposed experts in British Biotech companies lose all their money. Firstly AGL is listed on the AIM which in itself is questionable. Secondly the company has been going for about 15 years. Its about the same age as PYC. It listed at a time when tiny British Biotechs were all the rage. At the last interims to 31/10/2017 revenue was just £200k for crying out and losses were £3.4m. In fact the Sunday Times article is old news and inaccurate. The company's report on 08/01/2018 showed the results were no different than the standard results just that the method of obtaining the results was different. They did not indicate an accuracy of 95.1% whilst results from other methods are lower. I have no doubt they are making some limited progress but you need to separate the company from the shenanigans of the AIM. Normally there are less than ten trades per day so the stock is not very liquid. You will be able to buy but not sell. If you are going to top up be careful. If the rise puts you into profit take advantage of it and reduce your holding. You will get another chance to top up at a cheaper price. turbocharge I have had this argument on many a thread. I am fully aware of the difference between the nominal value and the share price. When looking at future issues you look at the nominal value not the share price. Reason being the markets will try to sell you the stock at as close to the nominal value as possible that way the margin of profit is much large. If they are forward selling placing shares at 10p for 47p the profit margin is 37p. If they are forward selling placing shares at 40p for 47p the profit margin is only 7p. Read Full Thread Follow Reply
24/12/2017 11:06	alloa2003: Its that time of year - what are your predicitons for the AGL share price in 12 months? I will start at £2 a share :) Read Full Thread Follow Reply
13/9/2017 09:00	sicilian_kan: No miavoce I'm not suggesting that. That would be crazy to think. But companies have a degree of control over the release of news. E.g. when to sign the contract etc. They also have much greater control over when to time a placing and can time it around newsflow. So the two can go hand in hand and often do. Newland's problem is that he has left it far, far too late. I expect he initially would have preferred to place after the ovarian results, expecting the share price to rise, and then it didn't. Instead, the share price more than halved from its high. It kept on falling and was volatile. I doubt very much that this would have happened if Angle was well funded, which it is not. The market has driven the price down expecting funding needs and given the vagaries of the ovarian RNS with its claims of "up to 95%", which without more information as to what "up to" means is fairly useless. In summary, any fundraising in the 30p region will be a total failure. It will be raising funds at a near 5 year low, despite all the scientific progress. If you want any indictment on Newland, if he does place in the 30p region, that will be all the evidence you need to show his failings as a CEO. What Newland does is to head down incorrect paths (FDA approval), announcing unrealistic timetables (e.g. the repeated delays to ovarian), whilst looking after number one (i.e. himself) over and above the best interests of the company shareholders (his share sales and buybacks, accepting his far too high bonuses etc). For me, Newland has lost credibility. I just cannot rely upon his statements about timings etc. There are only so many times the pudding can (looking retrospectively) be overegged, however inadvertently. Of course, I accept that Angle has made massive progress scientifically and the company is a lot further ahead, but the share price is categorically in a bad, bad place. Many shareholders will be in a position of a loss and the potential dilution here will be significant. Yes, a deal or some other funding arrangement might come along that will be much better than a placing at these levels and could obviate the need for significant dilution. But given where the share price is, the market does not believe that this will be the case. The market may be wrong of course, but usually it is correct at times such as this one. Read Full Thread Follow Reply
11/6/2017 15:55	alloa2003: Personally I think if AGL had taken this slowly slowly approach a couple of years ago the share price would be much higher. We have suffered from mismanagement of expectations but hopefully the BOD have learnt a lesson. Let the results come through and let them speak for themselves. Trying to guess when the FDA might act on AGL's application(s) is a waste of time but good trial results will put more pressure on the FDA. Share price targets of £5 are unrealistic at this moment in time but we could have a game changing year and a rejuvenated share price. First of all we need to see constant positive news flow and better management of expectations. The recent research note suggesting a share price of 187p (from memory) seems ambitious but achievable in this very volatile area in which AGL operates. One of the other keys is to maximise the current benefits of Parsortix over competing system asap - that way we get a foothold in the market. Once we are there, the companies who operate in this area will not be changing their systems every 2 minutes and only then will we see the sales flow that everyone has been hoping for. Read Full Thread Follow Reply

Angle share price data is direct from the London Stock Exchange

add chat code

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P:43 V: D:20180818 12:20:47